Related Experiment Video

Updated: Mar 31, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy

Kyung S Lee1, Terrence R Burke2, Jung-Eun Park1

  • 1Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Trends in Pharmacological Sciences
|October 20, 2015
PubMed

Insights

Polo-like kinase 1 (Plk1) is crucial for cell division and cancer development. This review covers new Plk1 inhibitors targeting its kinase and polo-box domains for cancer therapy.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Polo-like kinase 1 (Plk1) is vital for cell proliferation.
  • Plk1 overexpression is linked to human cancers.
  • Plk1 is a promising anticancer drug target.

Purpose of the Study:

  • Summarize recent advances in Plk1 inhibitor development.
  • Highlight challenges in targeting Plk1.
  • Discuss novel strategies for next-generation Plk1 inhibitors.

Main Methods:

  • Review of recent scientific literature on Plk1 inhibitors.
  • Analysis of Plk1's kinase domain (KD) and polo-box domain (PBD).
  • Discussion of drug design and development strategies.

Main Results:

  • Plk1 inhibitors can target either the KD or PBD.
  • Recent progress has been made in developing inhibitors for both domains.
  • Challenges remain in optimizing inhibitor efficacy and specificity.

Conclusions:

  • Targeting Plk1 offers a promising therapeutic strategy for various cancers.
  • Further research into novel inhibitor designs is essential.
  • Next-generation Plk1 inhibitors hold potential for treating Plk1-associated disorders.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K